← Back to Screener
Jupiter Neurosciences, Inc. Common Stock (JUNS)
Price$0.46
Favorite Metrics
Price vs S&P 500 (26W)-80.17%
Price vs S&P 500 (4W)-4.14%
Market Capitalization$15.86M
All Metrics
Book Value / Share (Quarterly)$0.00
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-67.55%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-61.28%
Net Profit Margin (TTM)-11812.06%
EPS (TTM)$-0.25
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.25
EPS (Annual)$-0.25
ROI (Annual)-56.50%
Gross Margin (Annual)80.60%
Cash / Share (Quarterly)$0.11
ROA (Last FY)-155.37%
EBITD / Share (TTM)$-0.26
Operating Margin (TTM)-12884.31%
Cash Flow / Share (Annual)$-0.16
P/B Ratio276.25x
P/B Ratio (Quarterly)1067.68x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-67.83x
ROA (TTM)-202.56%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)0.65x
Quick Ratio (Quarterly)0.63x
3-Month Avg Trading Volume0.25M
52-Week Price Return-38.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.24
P/S Ratio (Annual)727.62x
Asset Turnover (Annual)0.00x
52-Week High$3.33
EPS Excl Extra (Annual)$-0.25
26-Week Price Return-71.42%
Quick Ratio (Annual)0.63x
13-Week Price Return-46.02%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)0.65x
Enterprise Value$17.371
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-39655.50%
Cash / Share (Annual)$0.11
3-Month Return Std Dev110.83%
Net Income / Employee (TTM)$-2
ROE (Last FY)-58.48%
Net Interest Coverage (Annual)-7.84x
EPS Basic Excl Extra (Annual)$-0.25
Total Debt / Equity (Quarterly)2.55x
EPS Incl Extra (TTM)$-0.25
Receivables Turnover (Annual)0.03x
ROI (TTM)-329.56%
P/S Ratio (TTM)727.62x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.23
Forward P/E8.83x
Price vs S&P 500 (52W)-73.26%
Year-to-Date Return-57.14%
5-Day Price Return9.57%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-1228.96%
Net Profit Margin (Annual)-39655.50%
Month-to-Date Return16.28%
EBITD / Share (Annual)$-0.26
Operating Margin (Annual)-40865.69%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.25
P/B Ratio (Annual)84.90x
Pretax Margin (TTM)-11812.06%
Book Value / Share (Annual)$0.13
Price vs S&P 500 (13W)-48.89%
Beta1.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-352.06%
52-Week Low$0.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JUNSJupiter Neurosciences, Inc. Common Stock | 727.62x | — | — | — | $0.46 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing a resveratrol-based therapeutic platform to address neuroinflammation in central nervous system diseases. Its lead candidate, JOTROL, targets conditions including Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.